Piramal Pharma's loss narrows to Rs82 crore in June quarter
The company is aiming to double its revenues to $2 billion by 2029-30, Piramal told Mint in a post-results interview.
The Mumbai-based firm plans to spend $100-125 million in 2025 on capacity expansion. '...but even to reach our 2029-30 goals, we will have to continue to spend on capex…obviously, there is maintenance and compliance capex, but we will continue to spend on de-bottlenecking and increasing capacities where needed,' Piramal said.
The company on Monday reported a 1% year-on-year decline in its June-quarter revenue at ₹ 1,934 crore, missing the Bloomberg estimate of ₹ 2,047 crore based on a poll of seven brokerages.
Its Ebitda fell 26% to ₹ 165 crore, with Ebitda margin contracting to 9% compared to 11% in Q1FY25. Ebitda is short for earnings before interest, taxes, depreciation, and amortization.
Its net loss stood at ₹ 82 crore, down 8% on-year.
The Saridon maker said the revenue was impacted by the destocking of one of its largest CDMO (Contract Development and Manufacturing Organization) products. It anticipated 2025-26 growth to remain muted due to this and funding uncertainty for biotechs in the US.
'What we're quite pleased at is that if you take away the de-stocking event, we've grown at mid-teens, and we've also seen a more balanced growth in our overseas sites,' Piramal said, adding that the second half of the fiscal year is expected to be stronger.
The company anticipates mid-single-digit revenue growth, mid-teens Ebitda growth, and an improvement in profitability in 2025-26, said Piramal. The firm expects a recovery in 2026-27, Piramal had told Mint in an earlier conversation.
In the first three months of 2025-26, Piramal Pharma commenced expansion of two of its US facilities, Lexington, Kentucky, and Riverview, Michigan, for which it had previously announced a $90 million investment.
The company has 15 global CDMO facilities, with four in North America, two in the UK and nine in India.
Piramal's focus on capacity expansion comes as interest in Indian CDMOs, especially those with niche and differentiated capabilities, grows.
As global pharma innovators and biotechs look at derisking their operations and shifting supply chains away from China, Indian firms are poised to grab a large share of this lucrative business.
While companies, including Piramal, have seen an increase in requests for proposals (RFPs), indicating growing interest, the switch to actual clients is still slow.
Piramal told Mint earlier that customers were pausing decision-making. Domestic factors in the US, like tax and interest rates and FDA funding cuts, were also slowing down biotech recovery.
Export-focused CDMO peers such as Divi's Laboratories, Sai Life Sciences, and Syngene International are also aggressively ramping up capacities.
Piramal is banking on its differentiated offerings for growth. Its Lexington and Riverview expansions will play a vital role in the development and manufacturing of antibody-drug conjugates (ADC).
ADCs are a type of cancer therapy designed to deliver chemotherapy directly to cells, and have seen huge interest from innovators over the last few years.
Piramal's differentiated products, including ADCs, sterile fill finish, payload link, high-potent APIs, and on-patent commercial product development, have been growing faster than the rest of the business, and 'will be the driver going forward', said Piramal.
The company is not exploring inorganic growth for its CDMO business yet.
'We would do licensing and brand acquisitions in the complex hospital generics business or the consumer healthcare business. I think those are the most likely candidates for acquisitions rather than more facilities and new capabilities,' said Piramal.
Piramal Pharma's stock price dipped over 3% to ₹ 196.8 per share on Tuesday morning on National Stock Exchange before settling at ₹ 206.03, up 0.82% at market close.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
9 minutes ago
- Mint
Beyond Square Footage: How Luxury Real Estate in India Is Being Redefined
Luxury real estate in India is no longer defined by marble floors or skyline views. A new class of homeowners, that includes startup founders and next generation family office leaders, is reshaping the idea of luxury to focus on lifestyle, legacy, and ease of living. Whether in South Mumbai, Delhi, Gurgaon, or Pune, today's discerning buyer is looking for long term value and a sense of community rather than just opulence. This evolution is visible in how developers are repositioning their offerings. The market is shifting from a 'buy and hold' mindset to a 'live and thrive' proposition. Custom layouts, wellness focused architecture, smart home technology, and integrated mobility are increasingly becoming part of the standard blueprint. According to Knight Frank, residences priced above ₹ 1 crore accounted for nearly 50 percent of all units sold across India's top eight cities in H1 2025. Mumbai recorded over 47,000 sales, with a strong tilt toward mid-premium and luxury segments. The National Capital Region led in premium share. At the same time, under-construction luxury homes in Mumbai saw prices rise by up to 44% year-on-year, the sharpest jump across major metros. According to ANAROCK, homes priced above ₹ 1.5 crore accounted for 42 percent of new launches across India's top seven cities in Q1 2025, underscoring a growing focus on high-value housing. This shift is being driven by both end-user aspiration and investor appetite. Meanwhile, emerging lifestyle-oriented micro-markets like Alibaug, Goa, and Pune's Kharadi point to a rising preference for real estate with experiential value - properties designed around wellness, mobility, and second-home potential. Today's luxury buyer is more strategic and value-focused. According to the recent EY–Julius Baer Indian Family Office Playbook, capital preservation remains a key priority for around one in four family offices. However, there is increasing allocation toward asset classes like real estate and global equities, suggesting a growing appetite for long-term utility and liquidity. Features like smart layouts, energy-efficient materials, and proximity to urban green zones are becoming non-negotiable. Developers are responding with modular architecture, digital concierge services, and wellness-enabled environments. These include private fitness areas, community gardens, spa facilities, and clean air systems. What was once an upgrade is now standard for premium living. Several developers are evolving their portfolios to meet new buyer expectations for livability, wellness, and design. Among the many developers participating in this evolution, Mumbai-based Hubtown Limited serves as one case study. With more than four decades of experience and a portfolio spanning over thirty million square feet, Hubtown has evolved from a builder into a placemaker with an emphasis on civic responsibility. Projects like 25 South in Prabhadevi and 25 Downtown in Mahalaxmi or 25 West in Bandra are designed for multigenerational families and combine spectacular views with customizable plans and large floor plates. In suburbs such as Ghatkopar and Chembur, developments like Rising City and Seasons aim to deliver connectivity and community within self contained residential environments. The company is also building commercial developments at Ahmedabad and Mehsana that cater to the growing interest in commercial markets outside traditional metros. Hubtown has also been active in social infrastructure. It executed one of Maharashtra's first private slum rehabilitation projects under which more than ten thousand homes were delivered free of cost to eligible families. The company also developed the India's first robotic public car park in Mumbai's upmarket Breach Candy and helped upgrade public bus depots in Gujarat. This demonstrates how private real estate can intersect with public benefit. Outlook: Purpose Is the New Premium The future of India's luxury real estate will be defined by developers who can combine adaptability, design integrity, and civic foresight. For a clientele that is both globally mobile and deeply rooted, real estate must be more than just real assets. It must deliver meaning, consistency, and long-term relevance. Hubtown's model, while one among many, illustrates how real estate players that understand changing buyer psychology and urban responsibility may be better positioned to navigate the next cycle of premium housing. Note to the Reader: This article is part of Mint's promotional consumer connect initiative and is independently created by the brand. Mint assumes no editorial responsibility for the content.
&w=3840&q=100)
Business Standard
11 minutes ago
- Business Standard
India has to now contend with CAP- China, America, Pak: Cong's dig at govt
After US President Donald Trump announced a 25 per cent tariff on India, the Congress on Thursday took a swipe at Prime Minister Narendra Modi, saying that he once spoke of the TOP -- Tomato, Onion, Potato -- challenges in prices, but the country now has to contend with the political challenges arising out of CAP -China, America, Pakistan. The opposition party said that on the one hand President Trump criticises India strongly and imposes penalties on it for trading with Russia, while on the other hand, just before the Iranian President's visit to Pakistan, he announces a big partnership with Pakistan for hydrocarbon exploration and development, alongside a trade deal. Congress general secretary in-charge of communications Jairam Ramesh said that President Trump is "piling it on India". In an X post, Ramesh wrote, "Since May 10, he has claimed 30 times that he stopped Operation Sindoor. These claims were made in four different countries. On June 18, he hosted the Pakistan Army Chief and the orchestrator of the Pahalgam terror attacks for lunch at the White House." "On July 30, he imposed a 25% tariff on US imports from India plus a penalty on India's oil and defence purchases from Russia. In addition, sanctions on at least six Indian companies were imposed for engaging with Iran," he said. On July 30, Trump also announced that the US will help Pakistan explore and develop its oil and gas reserves, Ramesh said, adding this comes on top of his full-throated support to Pakistan receiving financial assistance from the World Bank and the International Monetary Fund. "Prime Minister Modi once spoke of the TOP (Tomato, Onion, Potato) challenge in prices. Now India has to contend with the political challenge arising out of CAP (China, America, Pakistan)," Ramesh said. "He (Modi) invested very heavily in his personal friendship with President Trump, as he had done earlier with President Xi. Both have the full measure of the man now --? someone who can be managed easily by playing to his gigantic ego and self-obsession," the Congress leader said. In another post, Ramesh said, "President Trump criticises India imposes penalties on India for trading with Russia. He sanctions Indian companies for trading with Iran." But just before the Iranian President's visit to Pakistan, Trump announces a big partnership with Pakistan for hydrocarbon exploration and development - alongside a trade deal, he said. The remarks came a day after the US President announced the imposition of 25 per cent tariff on all goods coming from India starting August 1, plus an unspecified penalty on the country for buying Russian crude oil and military equipment. The announcement is being seen as a pressure tactic to get New Delhi to agree to demands made by the US, which has, in recent days, got favourable trade deals with major partners like Japan, the UK and the European Union. In a social media post, Trump termed India's trade policies as "most strenuous and obnoxious". "All things not good! India will therefore be paying a tariff of 25 per cent, plus a penalty for the above, starting on August first," Trump wrote. The penalty was announced as India has made large purchases of oil and military equipment from Russia. India is the first country Trump has slapped a penalty over Russian imports. Earlier, he had imposed high tariffs on China but refrained from levying any penalty despite Beijing being Russia's largest oil importer. On Wednesday, the Opposition parties slammed the government for the US' imposition of the tariff and penalties on Indian imports, and said that Prime Minister Modi's friendship with the US president meant little. Ramesh had said that Modi should take inspiration from former prime minister Indira Gandhi and stand up to the president of the United States.
&w=3840&q=100)
Business Standard
11 minutes ago
- Business Standard
Goldman Sachs, Bernstein, Nomura: Brokerages decode Trump India tariffs
Donald Trump's 25 per cent tariff on Indian goods triggered a sharp fall in the markets in with the S&P BSE Sensex slipping nearly 800-points in intraday deals before recovering partially. While brokerages see this as a knee-jerk reaction to the developments, they are hopeful that the final tariff will be lower – in the 15 – 20 per cent range as both countries are still trying to eke out a feasible solution. Meanwhile, here's how leading brokerages have interpreted the developments: Goldman Sachs While the surprise 25 per cent tariff announcement will likely impact earnings, if enforced, we think the incremental earnings drag would be relatively moderate. Only 2 per cent of MSCI India total revenues are derived from goods exporting sectors. As such, the direct tariff impact is relatively small, based on our baseline pass-through assumptions. Every 5 percentage point (pp) increase in US tariff rates could cause an 80 basis point (bp) incremental hit to MSCI India earnings per share (EPS) from direct and indirect channels. As such, we estimate about 2 per cent incremental hit to EPS if the new tariffs are enforced. While we are not making any changes to our EPS growth forecasts (currently at 12 per cent/14 per cent for CY25/26). Indian equities have significantly lagged broader emerging market (EM) equities year-to-date (by about 15pp); the underperformance is likely to extend in the near-term. Nomura The announced higher reciprocal tariff rate of 25 per cent, however, may be temporary, and might settle down lower. The US trade delegation is set to visit India at end-August as part of this process. Hence, the elevated tariffs announced by the US are unlikely to be permanent, in our view, although the best-case outcome would be tariffs in the 15-20 per cent range. Over the medium-term, we would still expect India to remain a beneficiary of the China plus one strategy. Higher tariffs from the US could add downside risks to the RBI's FY26 GDP growth forecast of 6.5 per cent. Already, high frequency data point to a sluggish Q2 , with subdued urban consumption, weak private capex and moderating credit growth. Higher tariffs and pressure to curb Russian energy will further drag down growth due to weaker net exports. We maintain that the Reserve Bank of India's (RBI's) rate cutting cycle is not over, despite the change in its stance to neutral. We expect 25bp cuts each in October and December to a terminal repo rate of 5.00 per cent by end-2025, with risks skewed towards further cuts. Bernstein The best news, for now, is the fact that services remains outside this ambit, a place where serious macro dents can happen. UK, EU and Japan have forged a trade deal. Indonesia enjoys 19 per cent, Japan 15 per cent while Vietnam is at 20 per cent. India is no longer attractively placed in the pecking order. The worse could well be coming, as if China somehow settles at 34 per cent, which was the original plan, this would get the India-China differential really low, simply not high enough for India to have a meaningful China+1 impact. Angel One Export-oriented stocks can underperform in the near-term. Investor sentiment till trade talks turn positive from here is expected to remain cautious. FPIs may adopt a wait-and-watch stance till further clarity comes in or their stance may lead towards a sector rotation approach. Investors (domestic & foreign) are expected to shift their focus towards domestic growth, consumption, infrastructure and financial companies that rely less on exports. PL Capital Tariff announcement is much beyond trade and has far bigger geopolitical implications on the ongoing bilateral relations between India and US since Operation Sindoor. The roots of this aggression lie in Indian denial of US role in ceasefire with Pakistan; sustained buying of Russian crude; continuous status of Russia as a key defence supplier; and growing strategic overtures of BRICS and attempts at forging a RIC (Russia, India, China) block which might disturb US geopolitical interests in SE Asia. Probability of shifting of defence procurement away from USA post Operation Sindoor, might have led to sudden imposition of tariffs and penalty. We believe this attempt by US is a bullying tactic, which has also been used against some other countries, including Canada. We expect increase in uncertainty and market volatility in the near-term. Companies that have higher US exports might see increased volatility. Domestic consumption, hospitals, select consumer, Infra, capital Goods, AMC and private banks will act as a defensive hedge during these volatile times. Barclays We do not see this 25 per cent tariff threat impacting GDP growth meaningfully, pegging the likely impact at around 30bp. We expect near-term pressure to be maintained. The rupee looks oversold in the short term. Clearly, USD-INR has bounced more than anticipated, but we think the February high of just under 88.0 remains a strong resistance level. The INR also remains cheap in both NEER and REER terms, which could mean more of an inclination from the RBI to intervene to cap weakness.
